PUBLICATIONS & POSTERS

 
 

PUBLICATIONS

 
 

APR 2015


OncoImmunology. 2014; 3: e970914. Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells. Bae J, Samur M, Munshi A, Hideshima T, Keskin D, Kimmelman A, Lee A-H, Dranoff G, Anderson KC, Munshi NC.

DEC 2014


MAY 2014

Leukemia. 2014 May 14; 12-1. A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients. Bae J, Prabhala R, Voskertchian A, Brown A, Maguire C, Richardson P, Dranoff G, Anderson KC, Munshi NC.


SEP 2012

Clin Cancer Res. 2012 Sep 1; 18(17):4850-60. Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Bae J, Smith R, Daley J, Mimura N, Tai YT, Anderson KC, Munshi NC.


JUN 2012

Br J Haematol. 2012 Jun; 157(6):687-701. A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma. Bae J, Song W, Smith R, Daley J, Tai YT, Anderson KC, Munshi NC.


NOV 2011


OCT 2011

Leukemia. 2011 Oct; 25(10):1610-9. Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma. Bae J, Carrasco R, Lee AH, Prabhala R, Tai YT, Anderson KC, Munshi NC.

matrix_fade.jpg

POSTERS / ABSTRACTS

 

Blood. 2017; 130. Pembrolizumab (anti-PD-1) treatment increases anti-tumor activities of XBP1/CD138/CS1-specific cytotoxic T lymphocytes against multiple myeloma. Jooeun Bae, Derin Keskin, Yu-Tzu Tai, Teru Hideshima, Nikhil C. Munshi, Kenneth C. Anderson. (ASH Annual Meeting Abstract #1867)

2017


Journal of Cancer Science & Therapy. 2017; 9:4. Identification and Validation of HLA-A24 XBP1, CD138, CS1 Peptides: Induction of antigens-specific CD8 T cell Immunity using a Multi-peptide Cocktail. Preclinical basis for vaccine therapy in HLA-A24 patients with multiple myeloma and other cancers. Jooeun Bae, Derin Keskin, Jun Zhou, Guanglan Zhang, Dharminder Chauhan, Teru Hideshima, Noopur Raje, Paul Richardson, Nikhil Munshi and Kenneth C Anderson. (Global Summit on Oncology &  Cancer 2017)

2017


2016

Blood. 2016; 128. Final Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). Nooka AK, Wang M, Yee AJ, Thomas SK, O’Donnell EK, Shah JJ, Kaufman JL, Lonial S, Richardson PG, Raje NS. (ASH Annual Meeting Abstract #2124)


2015

Blood. 2015; 126. Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). Nooka AK, Wang M, Yee AJ, Thomas SK, O’Donnell EK, Shah JJ, Kaufman JL, Lonial S, Richardson PG, Raje NS. (ASH Annual Meeting Abstract #4246)


2014

Blood. 2014; 124. Initial Results of a Phase 1/2a, Dose Escalation Study of PVX-410 Multi-Peptide Cancer Vaccine in Patients with Smouldering Multiple Myeloma (SMM). Wang M, Nooka AK, Yee AJ, Thomas SK, O'Donnell EK, Shah J, Weber DM, Kaufman JL, Lonial S, Avigan D, Raje N. (ASH Annual Meeting Abstract #4737)


2014

AACR. 2014. Novel heteroclitic XBP1 peptides induce antigen-specific memory CD3+CD8+ T cells expressing critical T cell markers and transcription regulators. Bae J, Prabhala R, Carrasco R, Lee AH, Kimmelman A, Anderson KC, Munshi NC. (AACR Annual Meeting Abstract #2894)


2014

AACR. 2014. Lenalidomide treatment enhances the anti-tumor activities of XBP1 specific cytotoxic T lymphocytes by increasing the frequency and tumor-specific response of central memory CD3+CD8+ T cells. Bae J, Prabhala R, Carrasco R, Richardson P, Dranoff G, Anderson KC, Munshi NC. (AACR Annual Meeting Abstract #638)


2013

J Clin Oncol. 2013; 31. Novel heteroclitic XBP1 peptides evoking antigen-specific cytotoxic T lymphocytes targeting various solid tumors. Bae J, Carrasco R, Daley J, Dranoff G, Anderson KC, Munshi NC. (ASCO Annual Meeting Abstract #3067)


2012

Blood. 2012; 120. Induction of T Cell Immunity Using a Multipeptide Cocktail Containing XBP1, CD138, CS1 Peptides in Smoldering Multiple Myeloma. Bae J, Prabhata RH, Song W, Tai YT, Anderson KC, Munshi NC. (ASH Annual Meeting Abstract #5039)


2007

Blood. 2007; 110. Identification of CS1 Peptides for Induction of Antigen-Specific CTLs in Multiple Myeloma. Weihua Song, MD, Yu-Tzu Tai, PhD, Tetsuro Sasada, PhD, Peter Burger, BS, Mariateresa Fulciniti, PhD, Xianfeng Li, MS, Kenneth C. Anderson, MD and Nikhil C. Munshi, MD. (ASH Annual Meeting Abstract #1611)


2005

Blood. 2005; 106. XBP-1 a Selective and Specific Target for Immunotherapy in Myeloma. Jooeun Bae, PhD, Ruben Carrasco, PhD, Kumar Sukhdeo, PhD, Pierfrancesco Tassone, MD, Paola Neri, MD, Tai Yu-Tzu, PhD, Xianfeng Li, BS, Rory Coffey, BS, Rao Prabhala, PhD, Kenneth Anderson, MD and Nikhil Munshi, MD. (ASH Annual Meeting Abstract #1594)


2005

Blood. 2005; 106. Development of Novel CD138 Antigen-Specific Peptide Capable of Eliciting Myeloma-Specific Cytotoxic T Lymphocytes Response. Jooeun Bae, PhD, Jeff Martinson, BS, Tai Yu-Tzu, PhD, Paola Neri, MD, Pierfrancesco Tassone, MD, Xianfeng Li, BS, Rory Coffey, BS, Zhinan Xia, PhD, Rao Prabhala, PhD, Kenneth Anderson, MD and Nikhil Munshi, MD. (ASH Annual Meeting Abstract #3465)


 
purple-matrix.jpg